BioSpace News Archive

Deal Underscores Yamaha Motor’s Focus in Driving Business Innovation in the Health Technology Sector

Contact Lens Wearers Can Now Recycle Their Contact Lenses and Blister Packs

Applied BioMath (www.appliedbiomath.com), today announced Lucia Wille, PhD, Head of Biology at Applied BioMath will present, “Quantitative Systems Pharmacology Model of Tau Spreading in Alzheimer’s Disease to Enable Drug Development” at the Tau2020 Global Conference occurring February 12-13, 2020 in Washington, D.C.

Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) applications for its antibody candidates,

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the opening of its new corporate headquarters, located at 800 Saginaw Drive in Redwood City, CA

Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2019 financial results on Thursday, Jan. 30, 2020, after the close of the U.S. financial markets.

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 24,523,750 shares of its common stock at a price of $4.25 per share, which included the exercise in full by the underwriters of their option to purchase up to 3,198,750 additional shares of common stock.

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) granted the Company’s motion to vacate and remand the Patent Trial and Appeal Board (PTAB) decision to invalidate U.S. Patent No. 9,249,149 (’149 patent).

Denali Therapeutics Inc. (NASDAQ: DNLI) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering of $150 million of shares of its common stock

Endo International plc (NASDAQ: ENDP) today announced that one of its operating companies, Par Pharmaceutical (Par), has begun shipping an authorized generic version of Allergan’s Carafate® (sucralfate) oral suspension 1gm/10 mL.